Summary & Overview
HCPCS J7181: Injection, Factor XIII A-Subunit (Recombinant), per IU
HCPCS Level II code J7181 designates the injectable recombinant factor XIII A-subunit, billed per international unit, used to treat factor XIII deficiency and related bleeding disorders. This national-level billing descriptor is important for claims processing, clinical supply management, and payer coverage determinations for a high-cost biologic agent administered parenterally.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical indication and service context, payer coverage considerations, and typical sites where the product is administered. The publication outlines expected billing practices, common modifiers in use, and how J7181 interfaces with infusion and hospital outpatient service lines.
The report provides benchmarks and policy context relevant to reimbursement and utilization oversight for recombinant factor products, highlights billing scenarios commonly encountered in infusion centers and inpatient settings, and summarizes coding points that affect claims adjudication. Data not available in the input is noted where applicable. The content is intended to support coding accuracy, administrative planning, and payer-provider communication at a national level.
Billing Code Overview
HCPCS Level II code J7181 represents an injection of factor XIII A-subunit (recombinant), billed per international unit (per IU). This code denotes administration of a recombinant coagulation factor used to replace or supplement factor XIII A-subunit in patients with deficiency.
-
Service type: Biological agent administration (recombinant coagulation factor)
-
Typical site of service: Hospital inpatient, hospital outpatient, or ambulatory infusion center where parenteral biologic factor replacement is administered
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with congenital Factor XIII deficiency or an acquired severe Factor XIII deficiency who requires replacement therapy to prevent or treat bleeding. The patient presents to an outpatient infusion center, hospital inpatient unit, or emergency department with spontaneous bleeding (such as delayed wound healing, recurrent soft tissue bleeding, or intracranial hemorrhage) or for scheduled prophylactic intravenous replacement. A hematologist or transfusion medicine specialist prescribes dosing in international units (IU) based on body weight and severity. Nursing staff prepare the sterile J7181 product (recombinant Factor XIII A-subunit) per manufacturer instructions, verify patient identity and informed consent, obtain baseline vital signs and bleeding assessment, establish IV access, and administer the calculated dose slowly while monitoring for infusion reactions. Post-infusion observation includes vital signs, assessment for hypersensitivity, and documentation of lot number and IU units administered. Billing uses J7181 reported per IU, with appropriate modifiers for setting, provider, or circumstances such as anaphylaxis, partial administration, or product wastage documented as required.
Coding Specifications
| Modifier | Description | When to Use |
|---|